Quarterly ResultAug 4, 2026, 01:46 PM
Novo Nordisk Raises 2026 Sales & Profit Outlook to 0% to -6%
AI Summary
Novo Nordisk raised its full-year 2026 adjusted sales and operating profit growth outlook at constant exchange rates (CER) to 0% to -6%, an improvement from the previous -4% to -12%. This positive revision is attributed to increased expectations for GLP-1 product sales. For Q2 2026, adjusted sales grew 7% at CER to DKK 78,488 million, and adjusted operating profit rose 11% at CER to DKK 33,389 million.
Key Highlights
- 2026 adjusted sales growth outlook raised to 0% to -6% at CER.
- 2026 adjusted operating profit growth outlook raised to 0% to -6% at CER.
- Q2 2026 adjusted sales increased 7% at CER to DKK 78,488 million.
- Q2 2026 adjusted operating profit increased 11% at CER to DKK 33,389 million.
- Previous 2026 adjusted sales growth outlook was -4% to -12% at CER.
- Previous 2026 adjusted operating profit growth outlook was -4% to -12% at CER.
- Non-adjusted 2026 sales growth mid-point guidance is 5% at CER.
- Non-adjusted 2026 operating profit growth mid-point guidance is 12% at CER.
Price Impact
More from NVO